Wednesday morning, Sirtris Pharmaceuticals, Inc. (SIRT), a biopharmaceutical company, announced initial public offering of 6.9 million shares of common stock, which included 900 thousand shares sold pursuant to the underwriters' exercise in full of their over-allotment option.The Cambridge, Massachusetts-based company focused on discovering and developing small molecule drugs to treat diseases of aging such as type 2 diabetes said all shares were sold at $10.00 per share, resulting in aggregate net proceeds to Sirtris of about $62.4 million after deducting underwriting discounts and commissions and estimated offering expenses.J.P. Morgan Securities Inc. acted as the sole book-running manager and CIBC World Markets Corp., Piper Jaffray & Co., JMP Securities LLC, and Rodman & Renshaw, LLC acted as co-managers for the offering.SIRT is currently up $0.33 or 2.61% and trades at $12.97.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.